Non-invasive optical imaging of matrix metalloproteinase activity with albumin-based fluorogenic nanoprobes during angiogenesis in amouse hindlimb ischemia model

Biomaterials

Volumn 34, Issue 28, 2013, Pages 6871-6881

  Ryu, Ju Hee ^a,b   Shin, Jung Youn ^b   Kim, Sun Ah ^a   Kang, Sun Woong ^a   Kim, Hyunjoon ^a   Kang, Seokyung ^b   Choi, Kuiwon ^a   Kwon, Ick Chan ^a,c   Kim, Byung Soo ^b   Kim, Kwangmeyung ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Seoul National University   (South Korea)

^c Korea University   (South Korea)

Author keywords

Albumin; Angiogenesis; Fluorescence; Matrix metalloproteinase; Molecular imaging

Indexed keywords

ALBUMIN; ANGIOGENESIS; HUMAN SERUM ALBUMINS; IMMUNOHISTOCHEMISTRY; INTRAVENOUS INJECTIONS; MATRIX METALLOPROTEINASES; NANOPARTICLE STRUCTURES; NEAR-INFRARED FLUOROPHORES;

CELL CULTURE; FLUORESCENCE; MAMMALS; MOLECULAR IMAGING; OPTICAL IMAGE STORAGE; PROBES;

NANOPROBES;

CHOLECYSTOKININ OCTAPEPTIDE; GELATINASE A; GELATINASE B; HUMAN SERUM ALBUMIN; MATRIX METALLOPROTEINASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG HALF LIFE; EX VIVO STUDY; FLUORESCENCE IMAGING; IN VITRO STUDY; IN VIVO STUDY; LIMB ISCHEMIA; MOUSE; NANOPROBE; NONHUMAN; PRIORITY JOURNAL; SCINTIGRAPHY; ZYMOGRAPHY;

ANIMALS; BLOTTING, WESTERN; FEMALE; HINDLIMB; HUMANS; IMMUNOHISTOCHEMISTRY; ISCHEMIA; MATRIX METALLOPROTEINASES; MICE; OPTICAL IMAGING; SERUM ALBUMIN;

ANIMALIA;

EID: 84879461320     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.05.074     Document Type: Article

References (31)

1. Huang P.-H., Chen Y.-H., Wang C.-H., Chen J.-S., Tsai H.-Y., Lin F.-Y., et al. Matrix metalloproteinase-9 is essential for ischemia-induced neovascularization by modulating bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2009, 29:1179-1184.
2. Johnson C., Sung H.-J., Lessner S.M., Fini M.E., Galis Z.S. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res 2004, 94:262-268.
3. Ryu J.H., Lee A., Huh M.S., Chu J., Kim K., Kim B.S., et al. Measurement of MMP activity in synovial fluid in cases of osteoarthritis and acute inflammatory conditions of the knee joints using a fluorogenic peptide probe-immobilized diagnostic kit. Theranostics 2012, 2:198-206.
4. Dejonckheere E., Vandenbroucke R.E., Libert C. Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. Drug Discov Today 2011, 16:762-778.
5. Muhs B.E., Plitas G., Delgado Y., Ianus I., Shaw J.P., Adelman M.A., et al. Temporal expression and activation of matrix metalloproteinases-2, -9, and membrane type 1-matrix metalloproteinase following acute hindlimb ischemia. JSurg Res 2003, 111:8-15.
6. Frisdal E., Teiger E., Lefaucheur J.P., Adnot S., Planus E., Lafuma C., et al. Increased expression of gelatinases and alteration of basement membrane in rat soleus muscle following femoral artery ligation. Neuropathol Appl Neurobiol 2000, 26:11-21.
7. Heo J.H., Lucero J., Abumiya T., Koziol J.A., Copeland B.R., del Zoppo G.J. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. JCereb Blood Flow Metab 1999, 19:624-633.
8. Cheung P.-Y., Sawicki G., Wozniak M., Wang W., Radomski M.W., Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000, 101:1833-1839.
9. Koivunen E., Arap W., Valtanen H., Rainisalo A., Medina O.P., Heikkila P., et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999, 17:768-774.
10. Yang J., Zhang Z., Lin J., Lu J., Liu B.-f., Zeng S., et al. Detection of MMP activity in living cells by a genetically encoded surface-displayed FRET sensor. Biochim Biophys Acta 2007, 1773:400-407.
11. Lauer-Fields J.L., Nagase H., Fields G.B. Development of a solid-phase assay for analysis of matrix metalloproteinase activity. JBiomol Tech 2004, 15:305-316.
12. Vandooren J., Geurts N., Martens E., Van den Steen P.E., Opdenakker G. Zymography methods for visualizing hydrolytic enzymes. Nat Meth 2013, 10:211-220.
13. Weissleder R., Pittet M.J. Imaging in the era of molecular oncology. Nature 2008, 452:580-589.
14. Zhang F., Huang X., Zhu L., Guo N., Niu G., Swierczewska M., et al. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 2012, 33:5414-5422.
15. Ryu J.H., Lee A., Chu J.-U., Koo H., Ko C.-Y., Kim H.S., et al. Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3-specific polymeric probe. Arthritis Rheum 2011, 63:3824-3832.
16. Lee S., Ryu J.H., Park K., Lee A., Lee S.-Y., Youn I.-C., et al. Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination invivo. Nano Lett 2009, 9:4412-4416.
17. Luo S., Zhang E., Su Y., Cheng T., Shi C. Areview of NIR dyes in cancer targeting and imaging. Biomaterials 2011, 32:7127-7138.
18. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. JControl Release 2008, 132:171-183.
19. Wagner S., Rothweiler F., Anhorn M.G., Sauer D., Riemann I., Weiss E.C., et al. Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 2010, 31:2388-2398.
20. Bunschoten A., Buckle T., Kuil J., Luker G.D., Luker K.E., Nieweg O.E., et al. Targeted non-covalent self-assembled nanoparticles based on human serum albumin. Biomaterials 2012, 33:867-875.
21. Bae S., Ma K., Kim T.H., Lee E.S., Oh K.T., Park E.-S., et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 2012, 33:1536-1546.
22. Na J.H., Koo H., Lee S., Min K.H., Park K., Yoo H., et al. Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models. Biomaterials 2011, 32:5252-5261.
23. Zhang J., Nie L., Razavian M., Ahmed M., Dobrucki L.W., Asadi A., et al. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation 2008, 118:1953-1960.
24. Yarbrough W.M., Mukherjee R., Escobar G.P., Mingoia J.T., Sample J.A., Hendrick J.W., et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 2003, 108:1753-1759.
25. McCann T.E., Kosaka N., Mitsunaga M., Choyke P.L., Gildersleeve J.C., Kobayashi H. Biodistribution and excretion of monosaccharide-albumin conjugates measured with invivo near-infrared fluorescence imaging. Bioconjug Chem 2010, 21:1925-1932.
26. Seo H.-S., Park J.-S., Han K.-Y., Bae K.-D., Ahn S.J., Kang H.A., et al. Analysis and characterization of hepatitis B vaccine particles synthesized from Hansenula polymorpha. Vaccine 2008, 26:4138-4144.
27. Hama Y., Urano Y., Koyama Y., Kamiya M., Bernardo M., Paik R.S., et al. Atarget cell-specific activatable fluorescence probe for invivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate. Cancer Res 2007, 67:2791-2799.
28. Furumoto K., Yokoe J.-I., Ogawara K.-i., Amano S., Takaguchi M., Higaki K., et al. Effect of coupling of albumin onto surface of PEG liposome on its invivo disposition. Int J Pharm 2007, 329:110-116.
29. Pansare V., Hejazi S., Faenza W., Prud'homme R.K. Review of long-wavelength optical and NIR imaging materials: contrast agents, fluorophores and multifunctional nano carriers. Chem Mater 2012, 24:812-827.
30. Ghaghada K.B., Bockhorst K.H.J., Mukundan S., Annapragada A.V., Narayana P.A. High-resolution vascular imaging of the rat spine using liposomal blood pool MR agent. Am J Neuroradiol 2007, 28:48-53.
31. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. JClin Oncol 2005, 23:7794-7803.